ERBB2 and breast cancer: However, this difference may be explained by the fact that the latter subtype (which includes triple-negative breast cancer and a large part of HER2-positive breast cancer) is intrinsically more aggressive, less respondent to therapies, and likely diagnosed at a more advanced stage than hormone receptor-positive cancers [24].